{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:31:53Z","timestamp":1793475113102,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recurrence following curative esophagectomy remains a major clinical challenge and is associated with poor prognosis. Treatment strategies for postoperative recurrent esophageal squamous cell carcinoma must be individualized based on recurrence patterns, prior treatment history, and patient-related factors. Locoregional recurrence and oligo-recurrence in some non-regional lymph nodes may still be amenable to curative-intent therapy, including salvage surgery and definitive chemoradiotherapy (CRT). Selection of optimal treatment should consider tumor burden, performance status, and prior radiation exposure. Salvage surgery offers favorable long-term outcomes in carefully selected patients, particularly when recurrence occurs in non-dissected regions. CRT remains a central treatment strategy for unresectable disease, whereas re-irradiation after prior radiotherapy carries a substantial risk of severe toxicity and requires cautious patient selection. Advances in radiotherapy techniques, including intensity-modulated radiotherapy and particle therapy, may improve therapeutic efficacy while reducing toxicity. In parallel, systemic therapies, particularly immune checkpoint inhibitors, have expanded treatment options; however, their role in locoregional recurrence remains to be fully defined. Importantly, prognostic factors should not only be considered descriptive variables but also integrated into clinical decision-making to distinguish candidates for curative versus palliative treatment. Future strategies integrating precision oncology and multimodal approaches are expected to further improve outcomes. Prospective studies are needed to establish optimal treatment algorithms.<\/jats:p>","DOI":"10.1007\/s10388-026-01234-y","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:14:10Z","timestamp":1784531650000},"page":"693-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment strategies for postoperative locoregional recurrent esophageal squamous cell carcinoma after curative resection: a narrative review"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-1577","authenticated-orcid":false,"given":"Keiichi","family":"Jingu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinako","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanae","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Uchimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"5","key":"1234_CR1","first-page":"3461","volume":"25","author":"H Kato","year":"2005","unstructured":"Kato H, Fukuchi M, Miyazaki T, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy. Anticancer Res. 2005;25(5):3461\u20137.","journal-title":"Anticancer Res"},{"issue":"2","key":"1234_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jamcollsurg.2003.10.005","volume":"198","author":"S Nakagawa","year":"2004","unstructured":"Nakagawa S, Kanda T, Kosugi S, et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198(2):205\u201311. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2003.10.005.","journal-title":"J Am Coll Surg"},{"issue":"10447","key":"1234_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/s0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(24)00745-1.","journal-title":"Lancet"},{"issue":"2","key":"1234_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jjco\/hyp167","volume":"40","author":"YK Niibe","year":"2010","unstructured":"Niibe YK, Hayakawa. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107\u201311. https:\/\/doi.org\/10.1093\/jjco\/hyp167.","journal-title":"Jpn J Clin Oncol"},{"key":"1234_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-19153-8","author":"L Goense","year":"2026","unstructured":"Goense L, Elliott JA, Markar SR, et al. Patterns, timing, and survival of recurrence after surgery for esophageal and junctional adenocarcinoma in the european multicentre ENSURE study. Ann Surg Oncol. 2026. https:\/\/doi.org\/10.1245\/s10434-026-19153-8.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1234_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/sla.0000000000005638","volume":"276","author":"MC Kalff","year":"2022","unstructured":"Kalff MC, Henckens SPG, Voeten DM, et al. Recurrent disease after esophageal cancer surgery: a substudy of the Dutch nationwide ivory study. Ann Surg. 2022;276(5):806\u201313. https:\/\/doi.org\/10.1097\/sla.0000000000005638.","journal-title":"Ann Surg"},{"issue":"1","key":"1234_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13014-017-0780-5","volume":"12","author":"H Yamashita","year":"2017","unstructured":"Yamashita H, Jingu K, Niibe Y, et al. Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients. Radiat Oncol. 2017;12(1):38. https:\/\/doi.org\/10.1186\/s13014-017-0780-5.","journal-title":"Radiat Oncol"},{"issue":"12","key":"1234_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/jjco\/hym138","volume":"37","author":"Y Shioyama","year":"2007","unstructured":"Shioyama Y, Nakamura K, Ohga S, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol. 2007;37(12):918\u201323. https:\/\/doi.org\/10.1093\/jjco\/hym138.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"1234_CR9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10388-022-00936-3","volume":"19","author":"R Ito","year":"2022","unstructured":"Ito R, Nakamura Y, Sunakawa H, et al. Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil\/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. Esophagus. 2022;19(4):645\u201352. https:\/\/doi.org\/10.1007\/s10388-022-00936-3.","journal-title":"Esophagus"},{"issue":"1","key":"1234_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijrobp.2011.06.1978","volume":"83","author":"K Jingu","year":"2012","unstructured":"Jingu K, Ariga H, Nemoto K, et al. Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):172\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.06.1978.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1234_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12508","volume":"30","author":"L Depypere","year":"2017","unstructured":"Depypere L, Lerut T, Moons J, et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2017;30(1):1\u20138. https:\/\/doi.org\/10.1111\/dote.12508.","journal-title":"Dis Esophagus"},{"issue":"2","key":"1234_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1245\/s10434-014-4008-8","volume":"22","author":"X Ma","year":"2015","unstructured":"Ma X, Zhao K, Guo W, et al. Salvage lymphadenectomy versus salvage radiotherapy\/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22(2):624\u20139. https:\/\/doi.org\/10.1245\/s10434-014-4008-8.","journal-title":"Ann Surg Oncol"},{"key":"1234_CR13","doi-asserted-by":"publisher","unstructured":"Mitamura A, Tsujinaka S, Nakano T, et al. Treatment strategies for locoregional recurrence in esophageal squamous-cell carcinoma: an updated review. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16142539.","DOI":"10.3390\/cancers16142539"},{"issue":"11","key":"1234_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21037\/atm.2019.04.64","volume":"7","author":"Z Wang","year":"2019","unstructured":"Wang Z, Lin S, Wang F, et al. Salvage lymphadenectomy for isolated cervical lymph node recurrence after curative resection of thoracic esophageal squamous cell carcinoma. Ann Transl Med. 2019;7(11):238. https:\/\/doi.org\/10.21037\/atm.2019.04.64.","journal-title":"Ann Transl Med"},{"issue":"6","key":"1234_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ejso.2018.11.002","volume":"45","author":"Z Faiz","year":"2019","unstructured":"Faiz Z, Dijksterhuis WPM, Burgerhof JGM, et al. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy. Eur J Surg Oncol. 2019;45(6):931\u201340. https:\/\/doi.org\/10.1016\/j.ejso.2018.11.002.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"1234_CR16","doi-asserted-by":"publisher","first-page":"e70248","DOI":"10.1002\/cnr2.70248","volume":"8","author":"A Katano","year":"2025","unstructured":"Katano A, Minamitani M, Ohira S, et al. Stereotactic body radiation therapy for oligometastatic recurrent esophageal squamous cell carcinoma: a retrospective cohort study from a single tertiary center. Cancer Rep (Hoboken). 2025;8(6):e70248. https:\/\/doi.org\/10.1002\/cnr2.70248.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"3","key":"1234_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jjco\/hyw195","volume":"47","author":"K Jingu","year":"2017","unstructured":"Jingu K, Umezawa R, Yamamoto T, et al. Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer. Jpn J Clin Oncol. 2017;47(3):200\u20135. https:\/\/doi.org\/10.1093\/jjco\/hyw195.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"1234_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10388-018-0622-z","volume":"15","author":"T Kawamoto","year":"2018","unstructured":"Kawamoto T, Nihei K, Sasai K, et al. Involved-field chemoradiotherapy for postoperative solitary lymph node recurrence of esophageal cancer. Esophagus. 2018;15(4):256\u201362. https:\/\/doi.org\/10.1007\/s10388-018-0622-z.","journal-title":"Esophagus"},{"issue":"1","key":"1234_CR19","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1186\/s12885-025-14797-3","volume":"25","author":"W Liu","year":"2025","unstructured":"Liu W, Ge D, Wang T, et al. Salvage involved-field versus extended-field chemoradiotherapy for postoperative lymph node metastasis in esophageal squamous cell carcinoma: a retrospective clinical study. BMC Cancer. 2025;25(1):1390. https:\/\/doi.org\/10.1186\/s12885-025-14797-3.","journal-title":"BMC Cancer"},{"issue":"3","key":"1234_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","volume":"108","author":"Q Liu","year":"2020","unstructured":"Liu Q, Zhu Z, Chen Y, et al. Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;108(3):707\u201315. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.05.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1234_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.21873\/invivo.13202","volume":"37","author":"Y Hiroshima","year":"2023","unstructured":"Hiroshima Y, Ishikawa H, Sumiya T, et al. Clinical impact of proton beam therapy for postoperative lymph node oligorecurrence of esophageal cancer. Vivo. 2023;37(3):1253\u20139. https:\/\/doi.org\/10.21873\/invivo.13202.","journal-title":"Vivo"},{"issue":"6","key":"1234_CR22","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jtho.2020.01.024","volume":"15","author":"CM DeCesaris","year":"2020","unstructured":"DeCesaris CM, McCarroll R, Mishra MV, et al. Assessing outcomes of patients treated with re-irradiation utilizing proton pencil-beam scanning for primary or recurrent malignancies of the esophagus and gastroesophageal junction. J Thorac Oncol. 2020;15(6):1054\u201364. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.024.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1234_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijrobp.2015.12.005","volume":"95","author":"A Fernandes","year":"2016","unstructured":"Fernandes A, Berman AT, Mick R, et al. A prospective study of proton beam reirradiation for esophageal cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):483\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.005.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"1234_CR24","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.21873\/anticanres.13007","volume":"38","author":"Y Isozaki","year":"2018","unstructured":"Isozaki Y, Yasuda S, Akutsu Y, et al. Salvage carbon-ion radiotherapy for isolated lymph node recurrence following curative resection of esophageal cancer. Anticancer Res. 2018;38(11):6453\u20138. https:\/\/doi.org\/10.21873\/anticanres.13007.","journal-title":"Anticancer Res"},{"issue":"4","key":"1234_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10388-022-00922-9","volume":"19","author":"K Jingu","year":"2022","unstructured":"Jingu K, Umezawa R, Yamamoto T, et al. Patterns of failure after salvage chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer: 20-year experience in a single institution in Japan. Esophagus. 2022;19(4):639\u201344. https:\/\/doi.org\/10.1007\/s10388-022-00922-9.","journal-title":"Esophagus"},{"key":"1234_CR26","doi-asserted-by":"publisher","unstructured":"Zhang J, Peng F, Li N, et al. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. Radiat Oncol. 2012. https:\/\/doi.org\/10.1186\/1748-717x-7-93.","DOI":"10.1186\/1748-717x-7-93"},{"key":"1234_CR27","doi-asserted-by":"publisher","unstructured":"Bao Y, Liu S, Zhou Q, et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol. 2013;8:241. https:\/\/doi.org\/10.1186\/1748-717x-8-241.","DOI":"10.1186\/1748-717x-8-241"},{"issue":"1","key":"1234_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13014-017-0882-0","volume":"12","author":"K Jingu","year":"2017","unstructured":"Jingu K, Niibe Y, Yamashita H, et al. Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study. Radiat Oncol. 2017;12(1):146. https:\/\/doi.org\/10.1186\/s13014-017-0882-0.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1234_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13014-022-02019-0","volume":"17","author":"KJ Lan","year":"2022","unstructured":"Lan KJ, Chen. Efficacy and safety of re-irradiation for locoregional esophageal squamous cell carcinoma recurrence after radiotherapy: a systematic review and meta-analysis. Radiat Oncol. 2022;17(1):61. https:\/\/doi.org\/10.1186\/s13014-022-02019-0.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1234_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13014-021-01828-z","volume":"16","author":"X Wu","year":"2021","unstructured":"Wu X, Hu X, Chen J, et al. A re-irradiation dose of 55\u201360 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy. Radiat Oncol. 2021;16(1):100. https:\/\/doi.org\/10.1186\/s13014-021-01828-z.","journal-title":"Radiat Oncol"},{"issue":"11","key":"1234_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11748-014-0444-4","volume":"62","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Mine S, Yamada K, et al. Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. Gen Thorac Cardiovasc Surg. 2014;62(11):685\u201392. https:\/\/doi.org\/10.1007\/s11748-014-0444-4.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"2","key":"1234_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0167-8140(01)00392-9","volume":"61","author":"K Nemoto","year":"2001","unstructured":"Nemoto K, Ariga H, Kakuto Y, et al. Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol. 2001;61(2):165\u20138. https:\/\/doi.org\/10.1016\/s0167-8140(01)00392-9.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1234_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/gut.37.2.174","volume":"37","author":"JL Raoul","year":"1995","unstructured":"Raoul JL, Le E, Pris\u00e9 B, Meunier, et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut. 1995;37(2):174\u20136. https:\/\/doi.org\/10.1136\/gut.37.2.174.","journal-title":"Gut"},{"issue":"3","key":"1234_CR34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ijrobp.2009.08.065","volume":"78","author":"JC Lu","year":"2010","unstructured":"Lu JC, Kong C, Tao H. Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010;78(3):710\u20134. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.065.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1234_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1634\/theoncologist.2019-0931","volume":"25","author":"B Chen","year":"2020","unstructured":"Chen B, Li Q, Li Q, et al. Weekly Chemotherapy of 5-fluorouracil plus cisplatin concurrent with radiotherapy for esophageal squamous cell carcinoma patients with postoperative locoregional recurrence: results from a phase II study. Oncologist. 2020;25(4):308\u2013e625. https:\/\/doi.org\/10.1634\/theoncologist.2019-0931.","journal-title":"Oncologist"},{"issue":"2","key":"1234_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12539","volume":"30","author":"PM Jeene","year":"2017","unstructured":"Jeene PM, Versteijne E, van Berge Henegouwen MI, et al. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment. Dis Esophagus. 2017;30(2):1\u20135. https:\/\/doi.org\/10.1111\/dote.12539.","journal-title":"Dis Esophagus"},{"key":"1234_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2407-12-542","volume":"12","author":"K Jingu","year":"2012","unstructured":"Jingu K, Matsushita H, Takeda K, et al. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC Cancer. 2012;12:542. https:\/\/doi.org\/10.1186\/1471-2407-12-542.","journal-title":"BMC Cancer"},{"key":"1234_CR38","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.1038\/srep08071","volume":"5","author":"WW Zhang","year":"2015","unstructured":"Zhang WW, Zhu YJ, Yang H, et al. Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma. Sci Rep. 2015;5:8071. https:\/\/doi.org\/10.1038\/srep08071.","journal-title":"Sci Rep"},{"issue":"16suppl","key":"1234_CR39","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.2024.42.16_suppl.4029","volume":"42","author":"K Jingu","year":"2024","unstructured":"Jingu K, Umezawa R, Yamamoto T, et al. A phase II study of radiotherapy combined with docetaxel, cisplatin, and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer. J Clin Oncol. 2024;42(16suppl):4029\u20134029. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4029.","journal-title":"J Clin Oncol"},{"key":"1234_CR40","doi-asserted-by":"publisher","unstructured":"Chen B, Liu S, Zhu Y et al. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab. Nat Commun. 2024;15(1):1919. https:\/\/doi.org\/10.1038\/s41467-024-46307-7","DOI":"10.1038\/s41467-024-46307-7"},{"key":"1234_CR41","doi-asserted-by":"publisher","unstructured":"Lander EM, Aushev VN, Huffman BM, et al. Circulating tumor DNA as a prognostic biomarker for recurrence in patients with locoregional esophagogastric cancers with a pathologic complete response. JCO Precis Oncol. 2024;8:e2400288. https:\/\/doi.org\/10.1200\/po.24.00288.","DOI":"10.1200\/po.24.00288"},{"issue":"11","key":"1234_CR42","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1002\/ctm2.1116","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Yu N, Cheng G, et al. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Clin Transl Med. 2022;12(11):e1116. https:\/\/doi.org\/10.1002\/ctm2.1116.","journal-title":"Clin Transl Med"},{"issue":"35","key":"1234_CR43","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/jco.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138\u201348. https:\/\/doi.org\/10.1200\/jco.20.01888.","journal-title":"J Clin Oncol"},{"key":"1234_CR44","doi-asserted-by":"publisher","first-page":"102024","DOI":"10.1016\/j.ctrv.2020.102024","volume":"86","author":"MJM van Velzen","year":"2020","unstructured":"van Velzen MJM, Derks S, van Grieken NCT, et al. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev. 2020;86:102024. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102024.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1234_CR45","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.18632\/aging.102917","volume":"12","author":"C Yuan","year":"2020","unstructured":"Yuan C, Xiang L, Cao K, et al. The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy. Aging. 2020;12(5):4603\u201316. https:\/\/doi.org\/10.18632\/aging.102917.","journal-title":"Aging"},{"issue":"5","key":"1234_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"key":"1234_CR47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ctro.2022.10.011","volume":"38","author":"X Wu","year":"2023","unstructured":"Wu X, Li Y, Zhang K, et al. Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: a real-world study. Clin Transl Radiat Oncol. 2023;38:130\u20137. https:\/\/doi.org\/10.1016\/j.ctro.2022.10.011.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"1234_CR48","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12885-020-06716-5","volume":"20","author":"H Bando","year":"2020","unstructured":"Bando H, Kotani D, Tsushima T, et al. TENERGY: multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. BMC Cancer. 2020;20(1):336. https:\/\/doi.org\/10.1186\/s12885-020-06716-5.","journal-title":"BMC Cancer"},{"issue":"13","key":"1234_CR49","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med"},{"key":"1234_CR50","doi-asserted-by":"publisher","first-page":"1608872","DOI":"10.3389\/fonc.2025.1608872","volume":"15","author":"M Wang","year":"2025","unstructured":"Wang M, Xiong C, Wang S, et al. Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis. Front Oncol. 2025;15:1608872. https:\/\/doi.org\/10.3389\/fonc.2025.1608872.","journal-title":"Front Oncol"},{"key":"1234_CR51","doi-asserted-by":"publisher","first-page":"101152","DOI":"10.1016\/j.currproblcancer.2024.101152","volume":"53","author":"A Jubashi","year":"2024","unstructured":"Jubashi A, Kotani D, Kojima T, et al. Current landscape of targeted therapy in esophageal squamous cell carcinoma. Curr Probl Cancer. 2024;53:101152. https:\/\/doi.org\/10.1016\/j.currproblcancer.2024.101152.","journal-title":"Curr Probl Cancer"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-026-01234-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:17:06Z","timestamp":1793474226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-026-01234-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1007\/s10388-026-01234-y","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}